Rates and predictors of remission in first-episode schizophrenia within 1year of antipsychotic maintenance treatment. Results of a randomized controlled trial within the German Research Network on Schizophrenia

Schizophrenia Research

Volumn 152, Issue 2-3, 2014, Pages 478-486

  Gaebel, Wolfgang ^a   Riesbeck, Mathias ^a   Wölwer, Wolfgang ^a   Klimke, Ansgar ^a,b   Eickhoff, Matthias ^a,c   von Wilmsdorff, Martina ^a   Heuser, Isabella ^d   Maier, Wolfgang ^e   Klosterkötter, Joachim ^f   Falkai, Peter ^g,k   Schlösser, Ralf ^h,i   Schmitt, Andrea ^j,k   Riedel, Michael ^k   Klingberg, Stefan ^l   Köpcke, Wolfgang ^m   Ohmann, Christian ⁿ   Möller, Hans Jürgen ^k  

^a Department of Orthopedic Surgery   (Germany)

^b Vitos Waldkrankenhaus Köppern ^*  (Germany)

^c Department of Psychiatry   (Germany)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e UNIVERSITY OF BONN   (Germany)

^f UNIVERSITY OF COLOGNE   (Germany)

^g UNIVERSITY OF GÖTTINGEN   (Germany)

^h FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

ⁱ AHG Römhild Clinic   (Germany)

^j UNIVERSITY OF HEIDELBERG   (Germany)

^k LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^l UNIVERSITY OF TÜBINGEN   (Germany)

^m UNIVERSITY OF MÜNSTER   (Germany)

ⁿ HEINRICH HEINE UNIVERSITY   (Germany)

more..

Author keywords

1 year remission rate predictors risperidone haloperidol; First episode; Schizophrenia

Indexed keywords

HALOPERIDOL; RISPERIDONE;

ADULT; ARTICLE; DOSE RESPONSE; ENDURING REMISSION; FEMALE; HUMAN; LOW DRUG DOSE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; NEGATIVE SYNDROME; OUTCOME ASSESSMENT; POSITIVE SYNDROME; PRIORITY JOURNAL; PSYCHOLOGIC ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; SCHIZOPHRENIA; SYMPTOM ASSESSMENT; SYMPTOMATIC REMISSION;

1-YEAR REMISSION RATE-PREDICTORS-RISPERIDONE-HALOPERIDOL; FIRST EPISODE; SCHIZOPHRENIA;

ANTIPSYCHOTIC AGENTS; BIOMEDICAL RESEARCH; FEMALE; FOLLOW-UP STUDIES; GERMANY; HUMANS; MALE; PREDICTIVE VALUE OF TESTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; REGRESSION ANALYSIS; SCHIZOPHRENIA;

EID: 84892884550     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2013.04.012     Document Type: Article

References (58)

1. Addington J., Addington D. Symptom remission in first episode patients. Schizophr. Res. 2008, 106:281-285.
2. Addington D., Addington J., Schissel B. A depression rating scale for schizophrenics. Schizophr. Res. 1990, 3:247-251.
3. Alvarez-Jiménez M., Gleeson J.F., Henry L.P., Harrigan S.M., Harris M.G., Killackey E., Bendall S., Amminger G.P., Yung A.R., Herrman H., Jackson H.J., McGorry P.D. Road to full recovery: longitudinal relationship between symptomatic remission and psychosocial recovery in first-episode psychosis over 7.5years. Psychol. Med. 2012, 42:595-606.
4. American Psychiatric Association (APA) Social and Occupational Functioning Assessment Scale (SOFAS). Diagnostic and Statistical Manual of Mental Disorders 2000, 817-818. American Psychiatric Association, Washington, DC. fourth edition (text revision).
5. American Psychiatric Association (APA) Practice guideline for the treatment of patients with schizophrenia. Am. J. Psychiatry 2004, 161 (Suppl.):1-56. second edition.
6. Andreasen N.C. Negative symptoms in schizophrenia. Arch. Gen. Psychiatry 1982, 39:784-788.
7. Andreasen N.C., Carpenter W.T., Kane J.M., Lasser R.A., Marder S.R., Weinberger D.R. Remission in schizophrenia: proposed criteria and rationale for consensus. Am. J. Psychiatry 2005, 162:441-449.
8. Birchwood M., Todd P., Jackson C. Early intervention in psychosis. The critical period hypothesis. Br. J. Psychiatry 1998, 172(Suppl.):53-59.
9. Bodén R., Sundström J., Lindström E., Lindström L. Association between symptomatic remission and functional outcome in first-episode schizophrenia. Schizophr. Res. 2009, 107:232-237.
10. Boter H., Peuskens J., Libiger J., Fleischhacker W.W., Davidson M., Galderisi S., Kahn R.S. Effectiveness of antipsychotics in first-episode schizophrenia and schizophreniform disorder on response and remission: an open randomized clinical trial (EUFEST). Schizophr. Res. 2009, 115:97-103. EUFEST study group.
11. Bradford D.W., Perkins D.O., Lieberman J.A. Pharmacological management of first-episode schizophrenia and related nonaffective psychoses. Drugs 2003, 63:2265-2283.
12. Cassidy C.M., Norman R., Manchanda R., Schmitz N., Malla A. Testing definitions of symptom remission in first-episode psychosis for prediction of functional outcome at 2years. Schizophr. Bull. 2010, 36:1001-1008.
13. Crespo-Facorro B., Pérez-Iglesias R., Mata I., Caseiro O., Martínez-Garcia O., Pardo G., Ramirez-Bonilla M., Pelayo-Terán J.M., Vázquez-Barquero J.L. Relapse prevention and remission attainment in first-episode non-affective psychosis. A randomized, controlled 1-year follow-up comparison of haloperidol, risperidone and olanzapine. J. Psychiatr. Res. 2011, 45:763-769.
14. de Haan L., Nimwegen L., Amelsvoort T., Dingemans P., Linszen D. Improvement of subjective well-being and enduring symptomatic remission, a 5-year follow-up of first episode schizophrenia. Pharmacopsychiatry 2008, 41:125-128.
15. Emsley R., Oosthuizen P.P., Kidd M., Koen L., Niehaus D.J., Turner H.J. Remission in first-episode psychosis: predictor variables and symptom improvement patterns. J. Clin. Psychiatry 2006, 67:1707-1712.
16. Emsley R., Rabinowitz J., Medori R. Remission in early psychosis: rates, predictors, and clinical and functional outcome correlates. Schizophr. Res. 2007, 89:129-139. Early, Psychosis Global Working Group.
17. Emsley R., Oosthuizen P., Koen L., Niehaus D.J., Medori R., Rabinowitz J. Remission in patients with first-episode schizophrenia receiving assured antipsychotic medication: a study with risperidone long-acting injection. Int. Clin. Psychopharmacol. 2008, 23:325-331.
18. Fleischhacker W., Bergmann K., Perovich R. The Hillside Akathisia Scale (HAS): a new rating instrument for neuroleptic-induced akathisia. Psychopharmacol. Bull. 1989, 25:222-226.
19. Frances A., Pincus H.A., First M.B. The Global Assessment of Functioning Scale (GAF). Diagnostic and Statistical Manual of Mental Disorders 1994, 32. American Psychiatric Association, Washington, DC. Fourth edition.
20. Gaebel W., Riesbeck M., Wölwer W., Klimke A., Eickhoff M., von Wilmsdorff M., Jockers-Scherübl M.C., Kühn K., Lemke M., Bechdolf A., Bender S., Degner D., Schlösser R., Schmidt L.G., Schmitt A., Jäger M., Buchkremer G., Falkai P., Klingberg S., Köpcke W., Maier W., Häfner H., Ohmann C., Salize H.J., Schneider F., Möller H.J. Maintenance treatment with risperidone or low-dose haloperidol in first-episode schizophrenia. One-year results of a randomized controlled trial within the German Research Network on Schizophrenia. J. Clin. Psychiatry 2007, 68(11):1763-1774.
21. Gaebel W., Riesbeck M., Wölwer W., Klimke A., Eickhoff M., von Wilmsdorff M., Lemke M., Heuser I., Maier W., Huff W., Schmitt A., Sauer H., Riedel M., Klingberg S., Köpcke W., Ohmann C., Möller H.J. Relapse prevention in first-episode schizophrenia: maintenance vs. intermittent drug treatment with prodrome-based early intervention. Results of a randomized controlled trial within the German Research Network on Schizophrenia. J. Clin. Psychiatry 2011, 72:205-218. German Study Group on First-Episode Schizophrenia.
22. Goldman H.H., Skodol A.E., Lave T.R. Revising Axis V for DSM-IV. A review of measures of social functioning. Am. J. Psychiatry 1992, 149:1148-1156.
23. Abnormal Involuntary Movement Scale (AIMS). ECDEU Assessment Manual for Psychopharmacology, Revised 1976, 534-537. US Dept Health, Education and Welfare, Washington, DC. W. Guy (Ed.).
24. Clinical Global Impressions (CGI) Scale. ECDEU Assessment Manual for Psychopharmacology, Revised 1976, 218-222. US Dept Health, Education, and Welfare, Washington, DC. W. Guy (Ed.).
25. Hamilton M. A rating scale for depression. J. Neurol. Neurosurg. Psychiatry 1960, 23:56-62.
26. Henry L.P., Amminger G.P., Harris M.G., Yuen H.P., Harrigan S.M., Prosser A.L., Schwartz O.S., Farrelly S.E., Herrman H., Jackson H.J., McGorry P.D. The EPPIC follow-up study of first-episode psychosis: longer-term clinical and functional outcome 7years after index admission. J. Clin. Psychiatry 2010, 71:716-728.
27. Hogan T.P., Awad A.G., Eastwood R.A. Self-report predictive of drug compliance in schizophrenia: reliability and discriminative ability. Psychol. Med. 1983, 13:177-183.
28. Jobe T.H., Harrow M. Long-term outcome of patients with schizophrenia: a review. Can. J. Psychiatry 2005, 50:892-900.
29. Kay S.R., Opler L.A., Fiszbein A. The Positive and Negative Syndrome Scale (PANSS) rating manual. Soc. Behav. Sci. 1986, 17:28-29. (Doc.).
30. Kemp R., David A. Psychological predictors of insight and compliance in psychotic patients. Br. J. Psychiatry 1996, 169:444-450.
31. Kirkpatrick B., Fenton W.S., Carpenter W.T., Marder S.R. The NIMH-MATRICS consensus statement on negative symptoms. Schizophr. Bull. 2006, 32:214-219.
32. Klingberg S., Schneider S., Conradt B., Schaub A., Wagner M., Wölwer W., Bechdolf A., Gaebel W., Buchkremer G. Individual psychological intervention for relapse prevention in post acute, first episode schizophrenia - 2-year follow-up of a multicentric randomized clinical trial 2013, (in preparation).
33. Lambert M., Naber D., Schacht A., Wagner T., Hundemer H.P., Karow A., Huber C.G., Suarez D., Haro J.M., Novick D., Dittmann R.W., Schimmelmann B.G. Rates and predictors of remission and recovery during 3years in 392 never-treated patients with schizophrenia. Acta Psychiatr. Scand. 2008, 118:220-229.
34. Leucht S., Lasser R. The concepts of remission and recovery in schizophrenia. Pharmacopsychiatry 2006, 39:161-170.
35. Levine S.Z., Rabinowitz J., Ascher-Svanum H., Faries D.E., Lawson A.H. Extent of attaining and maintaining symptom remission by antipsychotic medication in the treatment of chronic schizophrenia: evidence from the CATIE study. Schizophr. Res. 2011, 133:42-46.
36. Lieberman J.A., Perkins D., Belger A., Chakos M., Jarskog F., Boteva K., Gilmore J. The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches. Biol. Psychiatry 2001, 50:884-897.
37. Malla A., Norman R., Schmitz N., Manchanda R., Béchard-Evans L., Takhar J., Haricharan R. Predictors of rate and time to remission in first-episode psychosis: a two-year outcome study. Psychol. Med. 2006, 36:649-658.
38. Menezes N.M., Arenovich T., Zipursky R.B. A systematic review of longitudinal outcome studies of first-episode psychosis. Psychol. Med. 2006, 36:1349-1362.
39. Menezes N.M., Malla A.M., Norman R.M., Archie S., Roy P., Zipursky R.B. A multi-site Canadian perspective: examining the functional outcome from first-episode psychosis. Acta Psychiatr. Scand. 2009, 120:138-146.
40. Möller H.J., Riedel M., Jäger M., Wickelmaier F., Maier W., Kühn K.U., Buchkremer G., Heuser I., Klosterkötter J., Gastpar M., Braus D.F., Schlösser R., Schneider F., Ohmann C., Riesbeck M., Gaebel W. Short-term treatment with risperidone or haloperidol in first-episode schizophrenia: 8-week results of a randomized controlled trial within the German Research Network on Schizophrenia. Int. J. Neuropsychopharmacol. 2008, 11:985-997.
41. Müller M.J., Marx-Dannigkeit P., Schlösser R., Wetzel H., Addington D., Benkert O. The Calgary Depression Rating Scale for Schizophrenia: development and interrater reliability of a German version (CDSS-G). J. Psychiatr. Res. 1999, 33:433-443.
42. Naber D. A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables. Int. Clin. Psychopharmacol. 1995, 10(Suppl. 3):133-138.
43. Petersen L., Thorup A., Øqhlenschlaeger J., Christensen T.Ø., Jeppesen P., Krarup G., Jørrgensen P., Mortensen E.L., Nordentoft M. Predictors of remission and recovery in a first-episode schizophrenia spectrum disorder sample: 2-year follow-up of the OPUS trial. Can. J. Psychiatry 2008, 53:660-670.
44. Robinson D., Woerner M.G., Alvir J.M., Bilder R., Goldman R., Geisler S., Koreen A., Sheitman B., Chakos M., Mayerhoff D., Lieberman J.A. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch. Gen. Psychiatry 1999, 56:241-247.
45. Robinson D.G., Woerner M.G., McMeniman M., Mendelowitz A., Bilder R.M. Symptomatic and functional recovery from a first episode of schizophrenia or schizoaffective disorder. Am. J. Psychiatry 2004, 161:473-479.
46. Scandinavian Society of Psychopharmacology Committee of Clinical Investigations (UKU) The UKU Side Effect Rating Scale: scale for the registration of unwanted effects of psychotropics. Acta Psychiatr. Scand. 1987, 76(334, Suppl.):81-94.
47. Schooler N.R., Hogarty G.E., Weissman M.M. Social Adjustment Scale II (SAS II). Resource Materials for Community Mental Health Evaluators Publication No. (ADM) 290-330 1979, 79-328. Department of Health Education and Welfare, Washington, DC, US. W.A. Hargreaves, C.C. Attkisson, J.E. Sorenson (Eds.).
48. Simonsen E., Friis S., Haahr U., Johannessen J.O., Larsen T.K., Melle I., Opjordsmoen S., Rund B.R., Vaglum P., McGlashan T. Clinical epidemiologic first-episode psychosis: 1-year outcome and predictors. Acta Psychiatr. Scand. 2007, 116:54-61.
49. Simonsen E., Friis S., Opjordsmoen S., Mortensen E.L., Haahr U., Melle I., Joa I., Johannessen J.O., Larsen T.K., Røssberg J.I., Rund B.R., Vaglum P., McGlashan T.H. Early identification of non-remission in first-episode psychosis in a two-year outcome study. Acta Psychiatr. Scand. 2010, 122:375-383.
50. Simpson G.M., Angus J.W. A rating scale for extrapyramidal side effects. Acta Psychiatr. Scand. Suppl. 1970, 212:11-19.
51. Strauss J.S., Carpenter W. The prognosis of schizophrenia: rationale for a multidimensional concept. Schizophr. Bull. 1978, 4:56-67.
52. Üçok A., Serbest S., Kandemir P.E. Remission after first-episode schizophrenia: results of a long-term follow-up. Psychiatry Res. 2011, 189:33-37.
53. Ventura J., Subotnik K.L., Guzik L.H., Hellemann G.S., Gitlin M.J., Wood R.C., Nuechterlein K.H. Remission and recovery during the first outpatient year of the early course of schizophrenia. Schizophr. Res. 2011, 132:18-23.
54. Watt D.C., Katz K., Shepherd M. The natural history of schizophrenia: a 5-year prospective follow-up of a representative sample of schizophrenics by means of standardized clinical and social assessment. Psychol. Med. 1983, 13:663-670.
55. Wölwer W., Buchkremer G., Häfner H., Klosterkötter J., Maier W., Möller H.J., Gaebel W. German research network on schizophrenia - bridging the gap between research and care. Eur. Arch. Psychiatry Clin. Neurosci. 2003, 253:321-329.
56. World Health Organization (WHO) International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10) 1992, World Health Organization, Geneva, Switzerland.
57. Wunderink L., Nienhuis F.J., Sytema S., Wiersma D. Predictive validity of proposed remission criteria in first-episode schizophrenic patients responding to antipsychotics. Schizophr. Bull. 2007, 33:792-796.
58. Wunderink L., Sytema S., Nienhuis F.J., Wiersma D. Clinical recovery in first-episode psychosis. Schizophr. Bull. 2009, 35:362-369.